| scholarly article | Q13442814 |
| P50 | author | Bahriye Aktas | Q83188500 |
| Pawel Mach | Q87769838 | ||
| P2093 | author name string | Sabine Kasimir-Bauer | |
| Rainer Kimmig | |||
| Maren Bredemeier | |||
| Mitra Tewes | |||
| Philippos Edimiris | |||
| Jenny Wagner | |||
| Doreen Schellbach | |||
| P2860 | cites work | Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients | Q21284707 |
| HER-2 gene amplification can be acquired as breast cancer progresses | Q24563115 | ||
| Circulating tumor cells: approaches to isolation and characterization | Q24631347 | ||
| Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis | Q27024067 | ||
| Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 | ||
| Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines | Q28483475 | ||
| Molecular biomarker analyses using circulating tumor cells | Q28749394 | ||
| Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy | Q29617584 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data | Q30779447 | ||
| Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells | Q33285246 | ||
| HER2-positive circulating tumor cells in breast cancer | Q33802925 | ||
| Circulating tumor cells predict survival in early average-to-high risk breast cancer patients | Q33958981 | ||
| Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. | Q34038793 | ||
| Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer | Q34168398 | ||
| Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 | Q34402487 | ||
| Molecular profiling of single circulating tumor cells with diagnostic intention | Q34542660 | ||
| The HER family and cancer: emerging molecular mechanisms and therapeutic targets | Q34558080 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer | Q35007782 | ||
| Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. | Q35558093 | ||
| Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. | Q35558096 | ||
| The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients | Q35619770 | ||
| Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer | Q35653820 | ||
| Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. | Q35749122 | ||
| Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine | Q35909577 | ||
| TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer | Q36145430 | ||
| Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation | Q36316580 | ||
| Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells | Q36393149 | ||
| Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. | Q36406697 | ||
| HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. | Q36693285 | ||
| Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting | Q36747333 | ||
| Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer | Q36934364 | ||
| Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients | Q37038658 | ||
| The prognostic implications of circulating tumor cells in patients with breast cancer | Q37079905 | ||
| Role of epidermal growth factor receptor in breast cancer | Q37320346 | ||
| Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients | Q37360176 | ||
| Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells | Q37360230 | ||
| Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer | Q37560932 | ||
| Recent advances in the molecular characterization of circulating tumor cells | Q37693504 | ||
| Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? | Q37694203 | ||
| Molecular mechanisms of metastasis in breast cancer--clinical applications | Q37801264 | ||
| Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges | Q37904507 | ||
| HER2-positive DTCs/CTCs in breast cancer | Q38004902 | ||
| Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. | Q38364887 | ||
| Gene expression profiling of circulating tumor cells in breast cancer. | Q38470332 | ||
| PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer | Q38940270 | ||
| Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib | Q39027480 | ||
| Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay | Q39606153 | ||
| Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial | Q39712731 | ||
| Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. | Q39822968 | ||
| Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells | Q39874639 | ||
| Prognostic markers in triple-negative breast cancer | Q42505075 | ||
| Challenges in circulating tumour cell research | Q43500645 | ||
| Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients | Q44115632 | ||
| Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system | Q45733272 | ||
| Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies | Q46446226 | ||
| HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring | Q47583436 | ||
| Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients | Q47586016 | ||
| Circulating tumour cells in non-metastatic breast cancer: a prospective study | Q47652073 | ||
| Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. | Q51744140 | ||
| HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial | Q51751068 | ||
| Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. | Q53012804 | ||
| The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. | Q53127630 | ||
| Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. | Q54169673 | ||
| mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. | Q54377128 | ||
| Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance | Q69367626 | ||
| Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer | Q69900051 | ||
| Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer | Q78347889 | ||
| Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients | Q83978338 | ||
| High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients | Q84277674 | ||
| Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients | Q86179689 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 41677-41690 | |
| P577 | publication date | 2016-05-20 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment | |
| P478 | volume | 7 |
| Q91810001 | CTCs Expression Profiling for Advanced Breast Cancer Monitoring |
| Q64245475 | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
| Q39339875 | Circulating Tumor Cells as Cancer Biomarkers in the Clinic. |
| Q33674656 | Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer |
| Q41472132 | EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy |
| Q33648465 | ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer |
| Q41233528 | Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy |
| Q64243735 | Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution? |
| Q26741223 | The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells |
Search more.